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Muzaffar H. Qazilbash,1 Rima M. Saliba,1 Yago Nieto,1 Gaurav Parikh,1 Matteo Pelosini,1
Fatima B. Khan,1 Roy B. Jones,1 Chitra Hosing,1 Floralyn Mendoza,1 Donna M. Weber,2
Michael Wang,2 Uday Popat,1 Amin Alousi,1 Paolo Anderlini,1
Richard E. Champlin,1 Sergio Giralt, MD1Arsenic trioxide (ATO) is synergistic with ascorbic acid (AA) and melphalan against myeloma both in vitro
and in vivo. The aim of this randomized phase II trial was to determine the safety and efficacy of a combination
of ATO, melphalan, and AA as preparative regimen in 48 patients undergoing autologous hematopoietic stem
cell transplantation (ASCT) for multiple myeloma (MM). Forty-eight patients received melphalan 200 mg/m2
i.v. over 2 days and AA 1000 mg i.v. over 7 days in 3 treatment arms: no ATO (arm 1), ATO 0.15 mg/kg i.v. 7
days (arm 2), and ATO 0.25 mg/kg i.v. 7 days (arm 3). No dose-limiting toxicity, engraftment failure, or non-
relapse mortality (NRM) was seen in the first 100 days post-ASCT. Complete responses (CR) were seen in
12 of 48 patients (25%), with an overall response rate (ORR 5 CR 1 PR) of 85%. Median progression-free
survival (PFS) was 25months; median overall survival (OS) has not yet been reached. Therewas no significant
difference in CR, PFS, or OS among the 3 treatment arms, and no adverse effect of ATO on melphalan phar-
macokinetics. Addition of ATO1 AA to high-dose melphalan is safe and well tolerated as a preparative reg-
imen for MM.
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Multiple myeloma (MM) is a clonal disorder of
plasma cells affecting approximately 50, 000 patients
in the United States, with an annual incidence of about
20,000 new cases [1,2]. Over the last 20 years high-
dose therapy (HDT) and autologous hematopoietic
stem cell transplantation (ASCT) have evolved into
a safe and effective therapeutic approach for patients
with MM. When compared to standard chemother-
apy, intensified chemotherapy followed by ASCT has
been shown to prolong both event-free and overall sur-
vival (OS) in selected previously untreated patients
with myeloma. One comparative study and 2 random-
ized trials have shown survival benefits in favor of
ASCT of approximately 12 months [3-5]. Two other1Department of Stem Cell Transplantation and Cellular
py; and 2Department of Lymphoma and Myeloma, UT
Anderson Cancer Center, Houston, Texas.
isclosure: See Acknowledgments on page 1406.
dence and reprint requests: Muzaffar H. Qazilbash, MD,
tment of Blood and Marrow Transplantation, UT-M.D.
son Cancer Center, 1515 Holcombe Boulevard, Unit
ouston, TX 77030 (e-mail: mqazilba@mdanderson.org).
ugust 30, 2008; accepted September 23, 2008
/08/1412-0001$34.00/0
6/j.bbmt.2008.09.019randomized trials, however, failed to show this survival
benefit [6,7]. However, this approach is not curative,
and most patients undergoing ASCT for MM eventu-
ally develop disease recurrence [8].We and others have
shown that salvage ASCT can be safely performed at
relapse, with median remission duration between 6
and 12 months and an OS approaching 3 years [9,10].
Melphalan 200 mg/m2 i.v. is the standard condi-
tioning regimen used for ASCT in myeloma, with
dose reductions based on age and renal function [11-
13]. In nonrandomized studies and a registry analysis,
use of more intensive preparative regimens, such as
busulfan with melphalan, thiotepa, busulfan, and cy-
clophosphamide, or high-dose idarubicin, cyclophos-
phamide, and melphalan, did not result in better
outcomes than melphalan at a dose of 200 mg/m2
[14-16]. Arsenic trioxide (ATO) is an antineoplastic
chemotherapeutic agent approved for the treatment
of relapsed or refractory acute promyelocytic leukemia
[17,18]. The use of ATO to treat MM is supported by
preclinical studies where it was shown to inhibit
growth, reduce viability, and induce apoptosis in sev-
eral MM cell lines at concentrations that can be safely
achieved in patients [19-21]. The antitumor activity of
ATO is dependent upon the generation of reactive
oxygen species (ROS) that damage mitochondria. In
addition, critical intracellular antioxidant, free1401
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subsequently expelled out of the cell by multidrug re-
sistance efflux pumps. Agents such as ascorbic acid
(AA) that deplete GSH sensitize cells to ATO-induced
apoptosis and are expected to enhance the anti-MMef-
fects of ATO [22].
The combination of ATOwith the cytotoxic agent
melphalan helps to overcome the resistance to melpha-
lan both in vitro and in severe combined immunodefi-
cient-human (scid-hu) murine models of human
myeloma [23]. Adding AA to this combination regi-
men enhances anti-MM effects of the melphalan/
ATO combination both in vitro and in vivo [22,23].
Early clinical studies of ATO for patients with ad-
vanced refractory MM have demonstrated significant,
albeit minor, responses in approximately one-third of
patients with daily dosing schedules [24,25]. A phase
II trial for the safety and efficacy of melphalan, ATO
and AA (MAC) combination therapy was performed
in patients with MM who failed more than 2 different
prior regimens. Objective responses were seen in 31 of
65 (48%) patients, including 2 complete remission
(CR), 15 partial remission (PR), and 14 minor re-
sponses. Median pregression-free suvival (PFS) and
OS were 7 and 19 months, respectively. Specific grade
3 or 4 hematologic (3%) or cardiac adverse events oc-
curred infrequently. This steroid-free regimen was ef-
fective and well tolerated in this heavily pretreated
group, making it a potential therapeutic option for
patients with relapsed or refractory MM [26].
We conducted a randomized phase II trial with
a combination of high-dose melphalan, ATO, and
AA to evaluate its impact on safety, engraftment, re-
sponse rate, and survival. We also assessed the impact
of ATO on melphalan PK. We decided to use the
doses of ATO that were safely used in combination
with standard-dose melphalan and AA [26]. AA and
ATO were administered for 5 days before melphalan
to deplete GSH and generation of ROS, which in
turn, are expected to enhance the antimyeloma activity
of melphalan [20,21,24].Table 1. Treatment Schema
Arm 1 Arm 2 Arm 3
Melphalan Melphalan Melphalan
100 mg/m2 i.v.  days 100 mg/m2 i.v. 100 mg/m2 i.v.
24, 23 Days 24, 23 Days 24, 23
Ascorbic acid Ascorbic acid Ascorbic acid
1000 mg i.v. 1000 mg i.v. 1000 mg i.v.
Days 29 to 23 Days 29 to 23 Days 29 to 23
Arsenic trioxide Arsenic trioxide Arsenic trioxide
None 0.15 mg/kg 0.25 mg/kg
Days 29 to 23 Days 29 to 23METHODS
Patients
Forty-eight patients were randomized to 3 treat-
ment arms and received a single ASCT between April
2004 and August 2005 ClinicalTrials.gov Identifier:
NCT00661544). At study entry, 29 (60%) patients
had a partial response to induction therapy and had re-
ceived a median of 2 different induction regimens
(range: 1-3). Nineteen (40%) patients had relapsed re-
fractory disease and had received a median of 4 prior
regimens (range: 2-9).
Patient inclusion criteria were age \70 years,
Eastern Cooperative Oncology Group (ECOG)performance status of 0-2, left ventricular ejection
fraction (LVEF) of .40%, pulmonary diffusing ca-
pacity (DLCO) of .40%; serum concentration of
aspartate aminotransferase (AST) or alanine amino-
transferase (ALT) no higher than 4 times the upper
limit of normal; serum total bilirubin concentration
no greater than twice the upper limit of normal; cor-
rected QT interval on electrocardiogram\500 mil-
liseconds. Patients had to have measurable serum or
urine paraprotein. Patients agreed to use contracep-
tion, and a confirmed negative pregnancy test before
enrollment was required for women. All patients
gave written informed consent before entering the
study, which was obtained in accordance with the
Declaration of Helsinki, under the auspices of proto-
cols approved by the institutional review board.
Study Design and Treatment
Peripheral blood stem cells (PBSC) were mobi-
lized and collected following granulocyte colony-
stimulating factor (G-CSF) alone or chemotherapy
1G-CSF. All 48 patients received high-dose Melpha-
lan at 100 mg/m2 i.v. on days 24 and 23, and AA
1000 mg i.v. daily on days 29 to 23. Patients in
arm 1 did not receive ATO; patients in arm 2 received
ATO 0.15 mg/kg i.v. from days 29 to 23; patients in
arm 3 received ATO at 0.25 mg/kg from days 29 to
23 (Table 1). Melphalan was infused over 30 minutes
in 2 divided doses over 2 consecutive days. Unmanip-
ulated autologous stem cells were infused 48 hours
later. All patients received G-CSF, 5 mg/kg/day
from day 11 until the absolute neutrophil count
(ANC) was 0.5  109/L for 2 consecutive days, in ac-
cordance with our departmental guidelines. Oral lev-
ofloxacin, acyclovir, and fluconazole were given for
the duration of neutropenia. Blood products were
given for hemoglobin #8 g/dL and platelets\20 
109/L.
Statistical Methods
This is a randomized phase II trial of ATO-
containing preparative regimen for ASCT in MM.
All patients received a fixed dose of Melphalan
(200 mg/m2) and AA (1000 mg). A maximum of 48
patients were randomized fairly between no ATO,
Table 2. Patient Characteristics
Total
Arm 1
(N 5 16)
Arm 2
(N 5 17)
Arm 3
(N 5 15)
P
Value
Median age (range) 54 (35-70) 58 (49-69) 54 52 .4
Median interval
Diagnosis—ASCT
(months)
13.7 13.7 14.2 13.3 .5
IgG 22 8 8 6
IgA 16 5 5 6
Light chain only 10 3 4 3
Chromosomal
abnormalities
9 4 3 2 .5
b2 M >3 mg/L 14 2 6 6 .2
LDH >618 IU/L 15 5 8 2 .13
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7 days prior to ASCT. A Bayesian model and decision
rules were used to monitor the outcomes continuously
throughout the trial. Actuarial rates of OS and PFS
were estimated by the Kaplan-Meier method [27].
Prognostic factors for survival were evaluated using
Cox’s proportional hazards model for univariate anal-
yses. Statistical significance was defined at the .05 level.
Analysis was performed using STATA 7.0 (StataCorp.,
2001, Stata Statistical Software: Release 7.0. College
Station, TX).
Response Criteria
The primary endpoints were toxicity of the regi-
men and engraftment. The secondary endpoints were
response rates, PFS, and OS. Additional secondary
endpoint was the impact of ATO on melphalan PK.
Toxicity was graded according to National Cancer In-
stitute Common Terminology Criteria (version 3.1;
Bethesda, MD). Engraftment was defined as ANC of
.0.5 109/L for 2 consecutive days. Response or pro-
gression was assessed according to the criteria of the
European Group for Blood and Marrow Transplanta-
tion (EBMT) [28]. PFSwas time from the day of ASCT
to progression or time last known alive. OS was time
from the day ofASCT to death or time last known alive.
Pharmacokinetics
For melphalan PK, including area under the curve
(AUC) measurements, a series of timed blood speci-
mens, 5 mL per tube, were drawn on the days of mel-
phalan administration (days24 and23) and placed on
ice. Plasma was separated by centrifugation at 4C and
stored at 270C until analysis. After deproteinization
with perchloric acid, melphalan plasma levels were de-
termined by high-performance liquid chromatography
(HPLC) using dansyl-proline as internal standard.
Pharmacokinetic modeling employed WinNonlin 3.0
(Pharsight Corporation, Mountain View, CA) [29].
Samples for ATO blood level were drawn on day 0,
approximately 30 minutes prior to the stem cell infu-
sion. Measurement of elemental arsenic was per-
formed by inductively coupled mass spectrometry
(ICP-MS) [29].
Comorbidity Indices
Charlson comorbidity index (CCI) and Seattle’s
hematopoietic cell transplantation-specific comorbid-
ity index (HCT-CI) were used to score the comorbid-
ities [30,31].Albumin <3.5 g/dL 5 1 2 2 .9
Creatinine >1.5 mg/dL 4 1 3 0 .3
HCT CI $3 15 4 7 4 .8
Prior ASCT 12 2 4 6 .2
Relapsed at ASCT 19 3 8 8 .05
b2 M indicates beta 2 microglobulin; LDH, lactic dehydrogenase; ASCT,
autologous hematopoietic stem cell transplantation; HCT CI, hemato-
poietic stem cell transplantation comorbidity index.RESULTS
Patients
From April 2004 to August 2005, 48 patients were
randomly assigned to 3 treatment arms. Sixteen pa-tients were randomized to arm 1, 17 to arm 2 (ATO
0.15 mg/kg), and 15 patients were randomized to
arm 3 (ATO 0.25 mg/kg). Table 2 summarizes the
characteristics of the 48 patients treated on this study.
Median interval from diagnosis to ASCT was 14
months (3-93). The median age was 54 years (range:
35-70). According to International Staging System
(ISS) for MM [32], 17 (35%) patients had stage I, 17
(35%) had stage II, and 8 (16%) patients had stage
III disease. Nine patients (19%) had a clonal cytoge-
netic abnormality by conventional karyotypic analysis,
either at baseline or prior to ASCT. Four patients (8%)
had elevated serum creatinine (.1.5 mg/dL) at the
time of transplant.Stem Cell Mobilization and Engraftment
Forty-two (87%) patients were mobilized with ei-
ther G-CSF 10 mg/kg/day or pegylated G-CSF alone,
given subcutaneously. Six (12%) patients with high tu-
mor burden received chemotherapy 1 G-CSF 10 mg/
kg/day, with modified cyclophosphamide, vincristine,
adriamycin, and dexamethasone (CVAD) regimen to
achieve cytoreduction and mobilization [33]. The me-
dian CD341 cell dose infused was 4.6 106/kg (range:
2.7-10.1). Median time to ANC $500/dL was 9 days,
with no engraftment failures or delays in either the
control or ATO arms. Median time to platelet count
of $20  109/l was 10 days (range: 8-21).Treatment-Related Toxicity
No transplant-related mortality or engraftment
failure was seen in the first 100 days after ASCT. Tox-
icity was limited to grade 1 or 2 nausea, vomiting, and
diarrhea and was comparable in all 3 arms (Table 3).
Table 3. Adverse Events
Adverse Events
Overall
(n 5 48)
Arm 1
(n 5 16)
Arm 2
(n 5 17)
Arm 3
(n 5 15)
P
Value
Cardiac* Grade I 2 0 1 1 .8
Grade II 1 0 1 0 .9
GI: diarrhea Grade I 24 7 8 9 .7
Grade II 1 0 0 0 .6
GI: vomiting Grade I 16 4 7 5 .6
Grade II 2 1 0 1 .5
GI: nausea Grade I 24 8 10 6 .6
Grade II 12 1 4 7 .03
Grade III 2 1 1 0 .9
GI: stomatitis Grade I 7 2 3 2 .9
Grade II 5 2 1 2 .7
Grade III 1 0 0 1 .3
Hepatic† Grade I 1 0 1 0 .9
Renal‡ Grade I 1 0 1 0 .9
Grade II 2 0 2 0 .3
Skin rash Grade I 2 0 2 0 .3
Fever/infections Grade III 11 3 4 4 .9
*Pedal edema, hypertension, venous thromboembolism.
†Increase in AST, ALT.
‡Increase in serum creatinine.
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Figure 1. Kaplan-Meier estimates for OS and PFS probability for all 48
patients treated on the protocol.
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tween the 3 arms. Grade 2 cardiac toxicities consisting
of pedal edema, hypertension, and venous thrombo-
embolism was seen in 10% of patients. Eight patients
have died; 6 because of progressive disease, 1 from sep-
sis, and 1 patient died of pancreatic cancer that was un-
related to therapy.
Response Rates
Twelve of the 48 patients (25%) achieved a CR.
There was no significant difference between the 3
arms in terms of CR (25%, 23%, and 27%, respec-
tively; P 5 .9). Overall response rate (CR 1 PR) was
85%, with no significant differences between the 3
arms (87%, 70%, and 86%, respectively). Among pa-
tients receiving this regimen as consolidation of a first
remission the CR rates were 28%, 30%, and 22%, re-
spectively. Because of its small sample size (48 patients)
and randomization to 3 arms, this study was not statis-
tically empowered to detect the differences in response
between the 3 treatment arms.
Patients receiving CVAD1 G-CSF for mobilization.These
6 patients were evenly distributed between 3 treatment
arms (2 in each arm). Prior to ASCT, 3 patients had
a partial remission, whereas other 3 had primary re-
fractory or relapsed disease. One patient achieved
a CR, 4 achieved a PR, and 1 patient had stable disease.
The PFS and OS of these patients were not signifi-
cantly different from those mobilized with G-CSF
alone.
Survival and Prognostic Factors
The median follow-up among surviving patients
was 33 months (range: 13-44). The 3-year PFS andOS were projected at 25% and 82%, respectively. Me-
dian PFS was 25 months, whereas median OS has not
been reached (Figure 1). There was no significant dif-
ference in PFS or OS between the 3 treatment arms (P
5 6 and .3, respectively). (Figure 2A and B). Because of
its small sample size (48 patients) and randomization to
3 arms, this study was not statistically empowered to
detect the differences in PFS and OS among the 3
treatment arms.
We analyzed the impact of a number of prognostic
factors on 3-year PFS. We were unable to detect any
significant impact of the serum albumin, b2 microglo-
bulin or lactic dehydrogenase (LDH) level, disease sta-
tus, chromosomal abnormalities, prior ASCT, or the
HCT-CI index on the outcome.
Patients undergoing a salvage ASCT. We analyzed the
outcome of patients undergoing a second ASCT for
relapsed disease. In 12 patients with salvage ASCT,
2 achieved a CR (16%), 6 achieved a PR (50%)
with an overall relative risk (ORR) of 66%. Median
PFS was 12 months, and median OS has not been
reached.Pharmacokinetics
Melphalan pharmacokinetics was performed on 24
patients (arm 1: 9, arm 2: 8, arm 3: 7) for whom ade-
quate samples were collected. As shown in Figure 3,
the melphalan AUC remained unchanged regardless
of the presence of ATO, or its dose level. In arm 1,
the median AUC was 1525 mmol/min (range: 1200-
1850); in arm 2 median AUC was 1500 mmol/min
(range: 1250-2000), and in arm 3 it was 1275 mmol/
min (range: 1190-1475) (P 5 .6).
Median serum concentrations of dimethylarsonic
acid (DMA) on day 0 were 0.2, 26.3, and 46.2 ng/mL
in arms 1, 2, and 3, respectively, consistent with the
ATO dose in that arm.
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Figure 2. (A) Kaplan-Meier estimates for OS probability according to
randomization to 3 treatment arms (arm 1 5 no ATO, arm 2 5 ATO
0.15 mg/kg, arm 3 5 ATO 0.25 mg/kg). (B) Kaplan-Meier estimates for
PFS probability according to randomization to 3 treatment arms (arm
1 5 no ATO, arm 2 5 ATO 0.15 mg/kg, arm 3 5 ATO 0.25 mg/kg).
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Disease progression that is generally resistant to
chemotherapy is the most common cause of treatment
failure in MM. A number of approaches are being
studied to prevent the emergence of resistance and
achieve durable remission. These approaches include
the combination of existing and novel antimyeloma
agents in conventional doses [34], tandem ASCT
[35,36], maintenance therapy [37], and sequential au-
tologous and allogeneic transplantation [38]. Further-
more, rationally designed preparative regimens for
ASCT should also be explored. In this phase II ran-
domized trial, we tested 1 such combination, consist-
ing of ATO, high-dose melphalan, and AA. We
hypothesized that this combination would be safe,
and would enhance antimyeloma activity of melphalanwithout exacerbating toxicity [23]. As there are no data
to support the benefit of combining melphalan and
AA, we used this combination as control. The dose
of ATO was chosen based on documented safety of
with 0.15 mg/kg i.v. in acute promyelocytic leukemia
(APL) [16] and 0.25 mg/kg i.v. in MM [24]. AA in
a dose of 1000 mg/day i.v. has been reported to be safe
and effective in combination with ATO in MM [24].
The regimen was well tolerated. The inclusion of
ATO with HD melphalan was associated with accept-
able toxicity. QT interval prolongation or torsades de
pointes were not seen in the ATO-containing arms
[39]. We did not encounter leukocytosis or APL
differentiation syndrome in this trial [18]. That could
be explained by an abbreviated course of ATO (7
days only), the presence of high-dose melphalan in
the regimen, and perhaps the fact that this syndrome
is only seen in patients with APL [18]. There were no
engraftment delays or failures in ATO-containing
arms. There were no treatment-related deaths within
the first 100 days. That was significant because patients
up to age 70 were treated and 12 patients received a
salvage ASCT.
We did not detect any interaction between ATO
with melphalan PK at either dose level of ATO. This
important observation was not unexpected, as both
drugs follow different PK pathways. ATO is not pro-
tein bound, and is methylated in the liver to its major
metabolites monomethylarsonic acid and dimethylar-
sonic acid, which are mostly excreted into the urine.
In contrast, Melphalan is extensively protein bound
and undergoes spontaneous plasma hydrolysis to dech-
lorinated inert products.
At the time of this analysis, there was no significant
difference in PFS and OS between the 3 treatment
arms. Themedian PFSwas 25months, which is similar
to our historic data [10,40,41], although it may be
noted that approximately 40% of patients had relapsed
disease at transplant, and 25% had failed a prior
ASCT. We observed that patients with a prior
ASCT had a median PFS of 12 months, and the me-
dian OS has not yet been reached at the last follow-
up (median: 33 months). Because of a small number
of patients and events in each arm, the study was not
sufficiently powered to detect the difference in PFS
and OS between the 3 treatment arms.
Of note, 16 of the 19 patients with relapsed disease
were randomized to ATO-containing arms (P 5 .05),
but their PFS and OS were comparable to patients
treated on the control arm.
In summary, addition of ATO and AA to high-dose
melphalan is safe and well tolerated as a preparative
regimen for ASCT in patients withMM, including pa-
tients with relapsed and refractory disease. There was
no adverse impact of ATO on engraftment. Longer
follow-up is needed to assess the efficacy of this com-
bination.
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No Significant Impact Of ATO On Melphalan AUC
DL = Dose Level; DL1= no ATO, DL2 = ATO 0.15 mg/kg, DL3 = ATO 0.25 mg/kg
DL1 Day 1 n = 9
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Figure 3. Impact of ATO dose on melphalan AUC on the days of melphalan administration. AUC5 area under the curve; DL15 dose level 1/no ATO;
DL2 5 dose level 2/ATO 0.15 mg/kg; DL3 5 dose level 3/ATO 0.25 mg/kg.
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